Decoy Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash, cash equivalents, and restricted cash | $10,709,937 | $2,434,528 |
| Prepaid expenses and other current assets | 275,223 | 553,034 |
| Total current assets | 10,985,160 | 2,987,562 |
| Property and equipment, net | 40,559 | — |
| Other assets | 30,988 | 35,412 |
| Total assets | $11,056,707 | $3,022,974 |
| Liabilities, convertible preferred stock and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $940,586 | $936,994 |
| Accrued expenses and other current liabilities | 859,442 | 352,419 |
| Deferred revenue | 3,225,581 | — |
| Note payable | — | 221,866 |
| Due to related party | 139,823 | — |
| Other current liability | 2,306 | — |
| Total current liabilities | 5,167,738 | 1,511,279 |
| Total liabilities | $5,167,738 | $1,511,279 |
| Commitments and contingencies (Note 6) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 1,674 and 0 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 531,968 and 8,006 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 53 | 1 |
| Additional paid-in capital | 100,331,014 | 83,435,312 |
| Accumulated deficit | (94,442,098) | (81,923,618) |
| Total stockholders' equity | 5,888,969 | 1,511,695 |
| Total liabilities and stockholders' equity | $11,056,707 | $3,022,974 |
Historical common stock and additional paid-in capital amounts have been recast to reflect the 1-for-8, 1-for-15 and 1-for-12 reverse stock splits effected on June 14, 2024, August 15, 2025 and March 6, 2026, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.